Chimeric flavivirus vectors

Details Chimeric flavivirus vectors Chimeric flavivirus vectors

2002-05-31

2009-08-04

Campell, Bruce (Department: 1648)

Chemistry: molecular biology and microbiology

Vector, per se

C435S235100, C424S184100, C424S199100, C424S201100, C424S202100, C424S204100, C424S277100

Reexamination Certificate

active

07569383

ABSTRACT:
The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors.

REFERENCES:
patent: 6136561 (2000-10-01), Ivy et al.
patent: 6171854 (2001-01-01), Galler et al.
patent: 6184024 (2001-02-01), Lai et al.
patent: 6416763 (2002-07-01), McDonell et al.
patent: 6682883 (2004-01-01), Monath et al.
patent: 6878372 (2005-04-01), Monath et al.
patent: 2003/0194801 (2003-10-01), Bonaldo et al.
patent: 2004/0223979 (2004-11-01), Chambers et al.
patent: 2004/0259224 (2004-12-01), Guirakhoo
patent: 2005/0002968 (2005-01-01), Monath et al.
patent: 2005/0053624 (2005-03-01), Arroyo et al.
patent: 2007/0184469 (2007-08-01), Depres et al.
patent: WO 93/06214 (1993-04-01), None
patent: WO 98/37911 (1998-09-01), None
patent: WO 01/39802 (2001-06-01), None
patent: WO 02/072835 (2002-09-01), None
patent: WO 02/102828 (2002-12-01), None
patent: WO 03/063725 (2003-08-01), None
patent: WO 03/101397 (2003-12-01), None
patent: WO 03/103571 (2003-12-01), None
patent: WO 2004/045529 (2004-06-01), None
patent: WO 2005/040390 (2005-05-01), None
patent: WO 2005/049815 (2005-06-01), None
patent: WO 2005/082020 (2005-09-01), None
patent: WO 2006/044857 (2006-04-01), None
patent: WO 2006/116182 (2006-11-01), None
patent: WO 2007/051267 (2007-05-01), None
Chambers, T, et al, 1999 Journal of Virology vol. 73 (4), 3095-3101.
Dermine et al. (Biochem Biophys Acta 2004 Vol 1704, pp. 11-35).
Arroyo et al., “Molecular Basis for Attenuation of Neurovinlence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE),” J. Virology 75(2):934-942, 2001.
Bonaldo et al., “Surface Expression of an Immunodominant Malaria Protein B Cell Epitope by Yellow Fever Virus,” J. Mol. Biol 315:873-885, 2002.
Bonaldo et al., “The Yellow Fever 17D Vaccine Virus as a Vector for the Expression of Foreign Proteins: Development of the New Live Flavivirus Vaccines,” Mem Inst Oswaldo Cruz, Rio de Janeiro 95(Suppl. 1):215-223, 2000.
De Vries et al., “Genetic Manipulation of Equine Arteritis Virus Using Full-Length cDNA Clones: Separation of Overlapping Genes and Expression of a Foreign Epitope,” Virology 270:84-97, 2000.
Li et al., “Chimeric Influenza Virus Induces Neutralizing Antibodies and Cytotoxic T Cells against Human Immunodeficiency Virus Type 1,” J. Virology 67(11):6659-6666, 1993.
McAllister et al., “Recombinant Yellow Fever Viruses are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases,” J. Virology 74(19):9197-9205, 2000.
Rey et al., “The Envelope Glycoprotein from Tick-Borne Encephalitis Virus at 2 Å Resolution,” Nature 375:291-298, 1995.
Hurrelbrink et al., “Attenuation of Murray Valley Encephalitis Virus by Site-Directed Mutagenesis of the HInge and Putative Receptor-Binding Regions of the Envelope Protein,” Journal of Virology, 75:7692-7702, 2001.
Thomas J. Chambers et al., U.S. Appl. No. 09/121,587, “Chimeric Flavivirus Vaccines,” Filed: Jul. 23, 1998.
Thomas J. Chambers et al., U.S. Appl. No. 09/452,638, “Chimeric Flavivirus Vaccines,” Filed: Dec. 1, 1999.
Chambers et al., “Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties,” Journal of Virology 73:3095-3101 (1999).
Goryshin et al., “In5 In Vitro Transposition,” J. Biol. Chem. 273:7387-7374 (1998).
Guirakhoo et al., “Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine,” Journal of Virology 75(16):7290-7304 (2001).
Guirakhoo et al., “Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates,” Journal of Virology 74(12):5477-5485 (2000).
Kolaskar et al, “Prediction of Three-Dimensional Structure and Mapping of Conformational Epitopes of Envelope Glycoprotein of Japanese Encephalitis Virus,” Virology 261:31-42 (1999).
Monath et al., “Chimeric Yellow Fever Virus 170-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing inRhesusMonkeys,” Journal of Virology 74(4):1742-1751 (2000).
U.S. Appl. No. 08/807,445, filed Feb. 28, 1997, Chambers et al.
U.S. Appl. No. 09/007,664, filed Jan. 15, 1998, Chambers et al.
Allison et al., “Mapping of Functional Elements in the Stern-Anchor Region of Tick-Borne Encephalitis Virus Envelope Protein E,”J. Virology73:5605-5612, 1999.
Allison et al., “Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E,”J. Virology75:4268-4275, 2001.
Arroyo et al., “Yellow Fever Vector Live-Virus Vaccines: West Nile Virus Vaccine Development,”Trends Mol. Med.7:350-354, 2001.
Arroyo et al., “ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy,”J. Virology78:12497-12507, 2004.
Bancroff, “Current Status of Dengue Vaccines and Prospects for the Future,”Puerto Rico Health Sci. J.6(1):23-26, 1987. Abstract only.
Barrett, “Current Status of Flavivirus Vaccines,”Ann. N. Y. Acad. Sci.951:262-271, 2001.
Bonaldo et al., “Attenuation of Recombiinant Yellow Fever 17-D Viruses Expressing Foreign Protein Epitopes at the Surface,”J. Virology79:8602-8613, 2005.
Bonaldo et al., “Expression of Foreign Protein Epitopes at the Surface or Recombinant Yellow Fever 17D Viruses Based on Three-Dimensional Modeling of Its Envelope Protein,”Cell Biochem. Biophys.44:313-324, 2006.
Bray et al., “Construction of Intertypic Chimeric Dengue Viruses by Substitution of Structural Protein Genes,”Proc. Natl. Acad. Sci. U.S.A.88:10342-10346, 1991.
Bray et al., “Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence,”J. Virology72:1647-1651, 1998.
Cardosa, “Dengue Vaccine Design: Issues and Challenges,”British Med. Bull.54(2):395-405, 1998.
Carle et al., “Experiments on the Transmission of an Icterogenic Agent in Yellow Fever Vaccine to Horses and Swine,”J. Bacteriol.48:45-69, 1944.
Caufour et al., “Constuction, Characterization and Immunogenicity of Recombinant Yellow Fever 17D-Dengue Type 2 Viruses,”Virus Res.79:1-14, 2001.
Chambers et al., “Mutagenesis of the Yellow Fever Virus NS2B/3 Cleavage Site: Determinants of Cleavage Site Specificity and Effects on Polyprotein Processing and Viral Replication,”J. Virology69(3):1600-1605, 1995.
Chambers et al., “Vaccine Developement Against Dengue and Japanese Encephalitis: Report of a World Health Organization Meeting,”Vaccine15:1494-1502, 1997.
Chen et al., “Generation and Characterization of Organ-Tropism Mutants of Japaneses Encephalitis Virus In Vivo and In Vitro,”Virology223:79-88, 1996.
Cola et al., “Nucleotide and Complete Amino Acid Sequences of Kunjin Virus: Definitive Gene Order and Characteristics of the Virus-Specified Proteins,”J. Gen. Virol.69:1-21, 1988.
Davis et al., “West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expressions in Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays,”J. Virology75:4040-4047, 2001.
dos Santos et al., “Complete Nucleotide Sequence of Yellow Fever Virus Vaccine Strains 17DD and 17D-213,”Virus Res.35:35-41, 1995.
dos Santos et al., “Determinants in the Envelope E Protein and Viral RNA Helicase NS3 that Influence the Induction of Apoptosis in Response to Infection with Dengue Type 1 Virus,”Virology274:292-308, 2000.
Edelman et al., “Phase I Trial of 16 Formulations of a Tetravalent Live-Attenuated Dengue Vaccine,”Am. J. Trop. Med. Hyg.69(Suppl 6):48-60, 2003.
Galler et al., “The Yellow Fever 17D Vaccine Virus: Molecu

Affiliated with

Also associated with

Rating

Chimeric flavivirus vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric flavivirus vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric flavivirus vectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4129752